BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
10/24/2025 6:10:11 AM | Browse: 11 | Download: 91
 |
Received |
|
2025-06-10 07:29 |
|
Peer-Review Started |
|
2025-06-10 07:30 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2025-06-23 01:44 |
|
Revised |
|
2025-06-25 12:11 |
|
Second Decision |
|
2025-09-11 02:38 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2025-09-11 08:38 |
|
Articles in Press |
|
2025-09-11 08:38 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2025-10-17 08:51 |
|
Publish the Manuscript Online |
|
2025-10-24 06:10 |
| ISSN |
2218-4333 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Surgery |
| Manuscript Type |
Meta-Analysis |
| Article Title |
Neoadjuvant immunotherapy in resectable hepatocellular carcinoma: A meta-analysis of the current evidence
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Ottavia Cicerone, Barbara Oliviero, Stefania Mantovani, Laura Maiocchi, Valentina Ravetta, Francesca Berton, Salvatore Corallo, Alessandro Vanoli and Marcello Maestri |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Marcello Maestri, MD, PhD, Professor, General Surgery Unit I - Liver Service, Fondazione IRCCS Policlinico San Matteo, P.le Golgi 19, Pavia 27100, Italy. m.maestri@smatteo.pv.it |
| Key Words |
Hepatocellular carcinoma; Neoadjuvant immunotherapy; Immune checkpoint inhibitors; Liver resection; Resectable hepatocellular carcinoma; Preoperative treatment |
| Core Tip |
This meta-analysis evaluates the efficacy and safety of neoadjuvant immunotherapy in resectable hepatocellular carcinoma (HCC). Pooled data suggest that this approach is feasible, with moderate pathological response rates and high resection feasibility, without a significant increase in severe toxicities. Although evidence is still limited, early findings support further investigation in prospective trials to define optimal treatment strategies and identify biomarkers predictive of response. Neoadjuvant immunotherapy may represent a promising strategy to improve surgical outcomes and reduce early recurrence in resectable HCC. |
| Publish Date |
2025-10-24 06:10 |
| Citation |
<p>Cicerone O, Oliviero B, Mantovani S, Maiocchi L, Ravetta V, Berton F, Corallo S, Vanoli A, Maestri M. Neoadjuvant immunotherapy in resectable hepatocellular carcinoma: A meta-analysis of the current evidence. <i>World J Clin Oncol</i> 2025; 16(10): 110511</p> |
| URL |
https://www.wjgnet.com/2218-4333/full/v16/i10/110511.htm |
| DOI |
https://dx.doi.org/10.5306/wjco.v16.i10.110511 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
